Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 3, 2015, Pages 599-613

  Ng, Khai P ^a   Arnold, Julia ^a   Sharif, Adnan ^a   Gill, Paramjit ^a   Townend, Jonathan N ^a   Ferro, Charles J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

aldosterone; cardiovascular actions; chronic kidney disease; meta analysis; Mineralocorticoid receptor antagonists; safety; systematic review

Indexed keywords

MINERALOCORTICOID ANTAGONIST; POTASSIUM; CREATININE;

ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERKALEMIA; META ANALYSIS; MORBIDITY; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; SYSTEMATIC REVIEW; ARTERIAL WALL THICKNESS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; DIASTOLE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HEART STROKE VOLUME; HEART VENTRICLE; MORTALITY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL INSUFFICIENCY, CHRONIC; SYSTOLE; VASCULAR ENDOTHELIUM;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CREATININE; DIASTOLE; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; HEART VENTRICLES; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; ORGAN SIZE; OXIDATIVE STRESS; POTASSIUM; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; STROKE VOLUME; SYSTOLE; VASCULAR STIFFNESS;

EID: 84950323726     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320315575849     Document Type: Article

References (49)

1. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
2. Shavit L, Lifschitz MD, Epstein M,. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms. Kidney Int 2012; 81: 955-968.
3. Benavente D, Chue CD, Ferro CJ,. The importance of renin-angiotensin blockade in patients with cardio-renal disease. J Ren Care 2010; 36: 97-105.
4. Pitt B, Rossignol P,. Mineralocorticoid receptor antagonists in patients with end stage renal disease (ESRD) on chronic hemodialysis. J Am Coll Cardiol 2014; 63: 537-538.
5. Brown NJ,. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-167.
6. Chue CD, Townend JN, Steeds RP, et al. Arterial stiffness in chronic kidney disease: Causes and consequences. Heart 2010; 96: 817-823.
7. Bomback AS, Kshirsagar AV, Klemmer PJ,. Renal aspirin: Will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol 2009; 5: 74-75.
8. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551.
9. Bolignano D, Palmer SC, Navaneethan SD, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4: CD007004.
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097.
11. Ng KP, Ferro CJ,. Protocol: Systematic review of cardiovascular effects of mineralocorticoid receptor anatagonists in chronic kidney disease. PROSPERO 2013:CRD42013006795, http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42013006795 (. accessed 17 December 2013)
12. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
13. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
14. Abolghasmi R, Taziki O,. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011; 22: 75-78.
15. Bianchi S, Bigazzi R, Campese VM,. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123.
16. Boesby L, Elung-Jensen T, Klausen TW, et al. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One 2011; 6: e26904.
17. Boesby L, Elung-Jensen T, Strandgaard S, et al. Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4-a randomized controlled study. PLoS ONE 2013; 8: e64549.
18. Chrysostomou A, Pedaggogos E, McGregor L, et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
19. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512.
20. Edwards NC, Ferro CJ, Kirkwood H, et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010; 106: 1505-1511.
21. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012; 73: 447-454.
22. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
23. Esteghamati A, Noshad S, Jarrah S, et al. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: A randomized clinical trial. Nephrol Dial Transplant 2013; 28: 2823-2833.
24. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31: 59-67.
25. Guney I, Selcuk NY, Altintepe L, et al. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail 2009; 31: 779-784.
26. Hase M, Babazono T, Ujihara N, et al. Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Investig 2013; 4: 316-319.
27. Joffe HV, Kwong RY, Gerhard-Herman MD, et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007; 92: 2552-2558.
28. Lizakowski S, Tylicki L, Rutkowski P, et al. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease. Pol Arch Med Wewn 2013; 123: 221-227.
29. Matsumoto S, Takebayashi K, Aso Y,. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006; 55: 1645-1652.
30. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
31. Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292.
32. Morales E, Huerta A, Gutierrez E, et al. Efecto antiproteinurico del bloqueo del sistema renina-angiotensina-aldosterona (SRAA) en los pacientes obesos. Cual es la opcion terapeutica mas eficaz? Nefrologia 2009; 29: 421-429.
33. Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: A randomized placebo-controlled crossover study. Diabetes Med 2012; 29: e184-e190.
34. Nielsen SE, Schjoedt KJ, Rossing K, et al. Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. J Renin Angiotensin Aldosterone Syst 2013; 14: 161-166.
35. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
36. Saklayen MG, Gyebi LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: Results of a randomized, placebo-controlled, double-blind, crossover trial. J Invest Med 2008; 56: 714-719.
37. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
38. Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009; 20: 392-397.
39. Taheri S, Mortazavi M, Pourmoghadas A, et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012; 23: 507-512.
40. Takebayashi K, Matsumoto S, Aso Y, et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-2217.
41. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493.
42. Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1380-1387.
43. Zheng H, Qiu H, Liu X, et al. Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy. Pharm Care Res 2011; 11: 266-268.
44. Ziaee A, Vaezi AA, Oveisi S, et al. Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial. Caspian J Intern Med 2013; 4: 648-653.
45. Moranne O, Bakris G, Fafin C, et al. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol 2013; 8: 1694-1701.
46. McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-343.
47. Vardeny O, Cavallari LH, Claggett B, et al. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 2013; 6: 970-976.
48. Namsolleck P, Unger T,. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transpl 2014; 29 (Suppl. 1): i62-i68.
49. Bienvenu LA, Reichelt ME, Delbridge LM, et al. Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: A focus on the cardiomyocyte. Clin Sci (Lond) 2013; 125: 409-421.